{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:02:58Z","timestamp":1791475378508,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018916","name":"Suzhou Municipal Health Commission","doi-asserted-by":"publisher","award":["Suzhou Clinical Key Disease Project (LCZX202236)"],"award-info":[{"award-number":["Suzhou Clinical Key Disease Project (LCZX202236)"]}],"id":[{"id":"10.13039\/100018916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018916","name":"Suzhou Municipal Health Commission","doi-asserted-by":"publisher","award":["Suzhou Medical Key Support Subject Project"],"award-info":[{"award-number":["Suzhou Medical Key Support Subject Project"]}],"id":[{"id":"10.13039\/100018916","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This cross-sectional controlled study aims to characterize ocular manifestations and corneal microstructure via in vivo confocal microscopy (IVCM) in mainland Chinese patients with Fabry disease (FD). We evaluated 30 FD patients (mean age: 38\u2009\u00b1\u200914.41 years; range: 10\u201360 years), divided equally into enzyme replacement therapy (ERT)-treated and untreated groups, alongside 30 age- and gender-matched healthy controls. Slit-lamp examinations assessed ocular manifestations, while IVCM was employed to analyze corneal microstructure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eighteen FD patients presented with corneal verticillata (CV) opacities. High-reflective intracellular inclusions were identified in the corneal basal epithelial cells in the majority of FD patients (22 out of 30). IVCM detected increased dendritic cells (DCs) in three FD patients. The nerve fiber layer showed an increased corneal nerve tortuosity coefficient (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), decreased nerve fiber density (NFD) (<jats:italic>P<\/jats:italic>\u2009=\u20090.033), decreased nerve fiber length (NFL) (<jats:italic>P<\/jats:italic>\u2009=\u20090.012), and reduced fractal dimension (<jats:italic>P<\/jats:italic>\u2009=\u20090.010) in FD patients compared to healthy controls. Reduced transparency of the anterior corneal stroma and the presence of visible microdots were observed in 11 out of 30 FD patients. Endothelial morphological parameters in FD patients showed no obvious differences compared to healthy controls. \u03b1-galactosidase A (\u03b1-Gal A) activity was negatively correlated with Mainz Severity Score Index (MSSI) scores (<jats:italic>P<\/jats:italic>\u2009=\u20090.001), whereas plasma globotriaosylsphingosine (lyso-Gb3) levels and posterior capsular opacification exhibited a direct correlation with MSSI scores(<jats:italic>P<\/jats:italic>\u2009=\u20090.002). None of these changes showed significant differences in FD patients, regardless of ERT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study substantially enhances our understanding of FD-associated ocular alterations in the mainland Chinese demographic. The presence of CV opacities, posterior capsular opacification, or distinct changes observed in IVCM offers the potential for early detection of FD. Additionally, there is a notable increase in DCs and a positive correlation between posterior capsular opacification and MSSI scores. These findings support the integration of ocular biomarker screening into standardized FD diagnostic protocols to facilitate pre-symptomatic interventions, particularly in familial risk cohorts.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03940-9","type":"journal-article","created":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T18:52:05Z","timestamp":1754851925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ocular and confocal manifestations of Mainland Chinese with Fabry disease: a cross-sectional controlled study"],"prefix":"10.1186","volume":"20","author":[{"given":"Yao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasa","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0604-0532","authenticated-orcid":false,"given":"Xiaofeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,10]]},"reference":[{"key":"3940_CR1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/jpm13060904","volume":"13","author":"G Gambini","year":"2023","unstructured":"Gambini G, Scartozzi L, Giannuzzi F, Carl\u00e0 MM, Boselli F, Caporossi T, et al. Ophthalmic manifestations in Fabry disease: updated review. J Pers Med. 2023;13:904.","journal-title":"J Pers Med"},{"key":"3940_CR2","unstructured":"Human Gene Mutation Database [Internet]. Available from: https:\/\/www.hgmd.cf.ac.uk\/ac\/index.php"},{"key":"3940_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2215\/CJN.09480819","volume":"15","author":"E Svarstad","year":"2020","unstructured":"Svarstad E, Marti HP. The changing landscape of Fabry disease. Clin J Am Soc Nephrol CJASN. 2020;15:569\u201376.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"3940_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.sbi.2021.11.009","volume":"72","author":"F Chiti","year":"2022","unstructured":"Chiti F, Kelly JW. Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation. Curr Opin Struct Biol. 2022;72:267\u201378.","journal-title":"Curr Opin Struct Biol"},{"key":"3940_CR5","doi-asserted-by":"publisher","first-page":"129437","DOI":"10.1016\/j.bbagen.2019.129437","volume":"1864","author":"JJ Miller","year":"2020","unstructured":"Miller JJ, Kanack AJ, Dahms NM. Progress in the Understanding and treatment of Fabry disease. Biochim Biophys Acta BBA - Gen Subj. 2020;1864:129437.","journal-title":"Biochim Biophys Acta BBA - Gen Subj"},{"key":"3940_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.47162\/RJME.62.1.01","volume":"62","author":"I-R Dinu","year":"2021","unstructured":"Dinu I-R, Firu \u015e-G. Fabry disease\u2013current data and therapeutic approaches. Rom J Morphol Embryol. 2021;62:5.","journal-title":"Rom J Morphol Embryol"},{"key":"3940_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/biom11020271","volume":"11","author":"K Kok","year":"2021","unstructured":"Kok K, Zwiers KC, Boot RG, Overkleeft HS, Aerts JM, Artola M. Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions. Biomolecules. 2021;11:271.","journal-title":"Biomolecules"},{"issue":"1\u20132","key":"3940_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","volume":"137","author":"DP Germain","year":"2022","unstructured":"Germain DP, Altarescu G, Barriales-Villa R, Mignani R, Pawlaczyk K, Pieruzzi F, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1\u20132):49\u201361.","journal-title":"Mol Genet Metab"},{"key":"3940_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/bjo.2006.100602","volume":"91","author":"A Sodi","year":"2007","unstructured":"Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of fabry\u2019s disease: data from the Fabry outcome survey. Br J Ophthalmol. 2007;91:210.","journal-title":"Br J Ophthalmol"},{"key":"3940_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an Under-Recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138:338\u201346.","journal-title":"Ann Intern Med"},{"key":"3940_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/jimd.12228","volume":"43","author":"SJ van der Veen","year":"2020","unstructured":"van der Veen SJ, Hollak CE, van Kuilenburg AB, Langeveld M. Developments in the treatment of Fabry disease. J Inherit Metab Dis. 2020;43:908\u201321.","journal-title":"J Inherit Metab Dis"},{"key":"3940_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021;81:635\u201345.","journal-title":"Drugs"},{"key":"3940_CR13","doi-asserted-by":"publisher","first-page":"1025740","DOI":"10.3389\/fphar.2022.1025740","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Ren X, Zhang Y, Ding L, Huo M, Li Q. Fabry disease: mechanism and therapeutics strategies. Front Pharmacol. 2022;13:1025740.","journal-title":"Front Pharmacol"},{"key":"3940_CR14","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.3390\/ijms24054548","volume":"24","author":"I Iacobucci","year":"2023","unstructured":"Iacobucci I, Hay Mele B, Cozzolino F, Monaco V, Cimmaruta C, Monti M, et al. Enzyme replacement therapy for FABRY disease: possible strategies to improve its efficacy. Int J Mol Sci. 2023;24:4548.","journal-title":"Int J Mol Sci"},{"key":"3940_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/qjmed\/hcae025","volume":"117","author":"EA Idrus","year":"2024","unstructured":"Idrus EA, Iskandar E. Cornea verticillata in Fabry disease. QJM Int J Med. 2024;117:452\u20133.","journal-title":"QJM Int J Med"},{"key":"3940_CR16","first-page":"25","volume":"223","author":"P Fanlo","year":"2023","unstructured":"Fanlo P, Garralda A, G\u00f3mez-Cerezo J, Echeverria M, L\u00f3pez M, Heras H, et al. Results of the screening program for Fabry disease in patients with cornea verticillata at the university hospital of Navarre. Rev Cl\u00ednica Esp Engl Ed. 2023;223:25\u201331.","journal-title":"Rev Cl\u00ednica Esp Engl Ed"},{"key":"3940_CR17","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/biom12101460","volume":"12","author":"F Amodio","year":"2022","unstructured":"Amodio F, Caiazza M, Monda E, Rubino M, Capodicasa L, Chiosi F, et al. An overview of molecular mechanisms in Fabry disease. Biomolecules. 2022;12:1460.","journal-title":"Biomolecules"},{"key":"3940_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","volume":"360","author":"M Michaud","year":"2020","unstructured":"Michaud M, Mauhin W, Belmatoug N, Garnotel R, Bedreddine N, Catros F, et al. When and how to diagnose Fabry disease in clinical pratice. Am J Med Sci. 2020;360:641\u20139.","journal-title":"Am J Med Sci"},{"key":"3940_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry working group consensus document. Orphanet J Rare Dis. 2015;10:1\u201310.","journal-title":"Orphanet J Rare Dis"},{"key":"3940_CR20","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.2174\/1381612826666200317142412","volume":"26","author":"I Simonetta","year":"2020","unstructured":"Simonetta I, Tuttolomondo A, Daidone M, Miceli S, Pinto A. Treatment of anderson-fabry disease. Curr Pharm Des. 2020;26:5089\u201399.","journal-title":"Curr Pharm Des"},{"key":"3940_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","volume":"121","author":"M Arends","year":"2017","unstructured":"Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg AB, Hughes DA, et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab. 2017;121:157\u201361.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"3940_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","volume":"53","author":"A Ortiz","year":"2016","unstructured":"Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry registry. J Med Genet. 2016;53(7):495\u2013502.","journal-title":"J Med Genet"},{"issue":"4","key":"3940_CR23","first-page":"321","volume":"60","author":"Chinese Fabry Disease Expert Panel","year":"2021","unstructured":"Chinese Fabry Disease Expert Panel. Expert consensus for diagnosis and treatment of Fabry disease in China (2021). Zhonghua Nei Ke Za Zhi. 2021;60(4):321\u201330.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"3940_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416\u201327.","journal-title":"Mol Genet Metab"},{"key":"3940_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ajo.2005.11.053","volume":"141","author":"L Mastropasqua","year":"2006","unstructured":"Mastropasqua L, Nubile M, Lanzini M, Carpineto P, Toto L, Ciancaglini M. Corneal and conjunctival manifestations in Fabry disease: in vivo confocal microscopy study. Am J Ophthalmol. 2006;141:709\u2013709.","journal-title":"Am J Ophthalmol"},{"key":"3940_CR26","first-page":"17","volume":"90","author":"S Moiseev","year":"2018","unstructured":"Moiseev S, Ismailova D, Moiseev A, Bulanov N, Karovaikina E, Nosova N, et al. Cornea verticillata in Fabry disease. Ter Arkh. 2018;90:17\u201322.","journal-title":"Ter Arkh"},{"key":"3940_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0181-5512(05)81024-1","volume":"28","author":"L Fumex-Boizard","year":"2005","unstructured":"Fumex-Boizard L, Cochat P, Fouilhoux A, Guffon N, Denis P. Relation between ocular manifestations and organ involvement in ten patients with Fabry disease. J Fr Ophtalmol. 2005;28:45\u201350.","journal-title":"J Fr Ophtalmol"},{"key":"3940_CR28","doi-asserted-by":"publisher","first-page":"12244","DOI":"10.1038\/s41598-018-30688-z","volume":"8","author":"G Bitirgen","year":"2018","unstructured":"Bitirgen G, Turkmen K, Malik RA, Ozkagnici A, Zengin N. Corneal confocal microscopy detects corneal nerve damage and increased dendritic cells in Fabry disease. Sci Rep. 2018;8:12244.","journal-title":"Sci Rep"},{"key":"3940_CR29","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00417-011-1726-5","volume":"249","author":"J Wasielica-Poslednik","year":"2011","unstructured":"Wasielica-Poslednik J, Pfeiffer N, Reinke J, Pitz S. Confocal laser-scanning microscopy allows differentiation between Fabry disease and amiodarone-induced keratopathy. Graefes Arch Clin Exp Ophthalmol. 2011;249:1689\u201396.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"3940_CR30","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/bjophthalmol-2019-314249","volume":"104","author":"A Leonardi","year":"2020","unstructured":"Leonardi A, Carraro G, Modugno RL, Rossomando V, Scalora T, Lazzarini D, et al. Cornea verticillata in Fabry disease: a comparative study between slit-lamp examination and in vivo corneal confocal microscopy. Br J Ophthalmol. 2020;104(5):718\u201322.","journal-title":"Br J Ophthalmol"},{"key":"3940_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00417-008-0962-9","volume":"247","author":"K Falke","year":"2009","unstructured":"Falke K, B\u00fcttner A, Schittkowski M, Stachs O, Kraak R, Zhivov A, et al. The microstructure of cornea verticillata in Fabry disease and amiodarone-induced keratopathy: a confocal laser-scanning microscopy study. Graefes Arch Clin Exp Ophthalmol. 2009;247:523\u201334.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3940_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/acn3.275","volume":"3","author":"M Stettner","year":"2016","unstructured":"Stettner M, Hinrichs L, Guthoff R, Bairov S, Petropoulos IN, Warnke C, et al. Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. Ann Clin Transl Neurol. 2016;3:88\u2013100.","journal-title":"Ann Clin Transl Neurol"},{"key":"3940_CR33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta BBA-Mol Basis Dis. 2012;1822:226\u201332.","journal-title":"Biochim Biophys Acta BBA-Mol Basis Dis"},{"key":"3940_CR34","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2147\/OPTH.S66748","volume":"8","author":"PG Davey","year":"2014","unstructured":"Davey PG. Fabry disease: a survey of visual and ocular symptoms. Clin Ophthalmol Auckl NZ. 2014;8:1555\u201360.","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"3940_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4274\/tjo.galenos.2024.09482","volume":"54","author":"\u0130 Korkmaz","year":"2024","unstructured":"Korkmaz \u0130, Kalkan U\u00e7ar S, Onay H, Y\u0131ld\u0131r\u0131m S\u00f6zmen E, \u00c7oker M, Palamar M. Ocular manifestations of Fabry disease: report from a tertiary eye care center in T\u00fcrkiye. Turk J Ophthalmol. 2024;54:127\u201332.","journal-title":"Turk J Ophthalmol"},{"key":"3940_CR36","first-page":"221","volume":"12","author":"J Libert","year":"1976","unstructured":"Libert J, Tondeur M, Hoof FV. The use of conjunctival biopsy and enzyme analysis in tears for the diagnosis of homozygotes and heterozygotes with Fabry disease. Birth Defects Orig Artic Ser. 1976;12:221\u201339.","journal-title":"Birth Defects Orig Artic Ser"},{"key":"3940_CR37","doi-asserted-by":"publisher","first-page":"2226909","DOI":"10.1080\/07853890.2023.2226909","volume":"55","author":"Y Wu","year":"2023","unstructured":"Wu Y, Zhang W, Yao X, Song W, Zhao Y, Yuan Y, et al. Investigation of ocular involvement in patients with Fabry disease. Ann Med. 2023;55:2226909.","journal-title":"Ann Med"},{"key":"3940_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","volume":"123","author":"AAN B TPM","year":"2018","unstructured":"B TPM AAN, C TH, C JG. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123:148\u201353.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3940_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","volume":"59","author":"A Nowak","year":"2022","unstructured":"Nowak A, Beuschlein F, Sivasubramaniam V, Kasper D, Warnock DG. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J Med Genet. 2022;59(3):287\u201393.","journal-title":"J Med Genet"},{"key":"3940_CR40","first-page":"3733","volume":"15","author":"O Yan","year":"2018","unstructured":"Yan O, Bing C, Xiaoxia P, Zhaohui W, Hong R, Yaowen X, et al. Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease. Exp Ther Med. 2018;15:3733\u201342.","journal-title":"Exp Ther Med"},{"issue":"2","key":"3940_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ijns9020031","volume":"9","author":"V Gragnaniello","year":"2023","unstructured":"Gragnaniello V, Burlina AP, Commone A, Gueraldi D, Puma A, Porc\u00f9 E, et al. Newborn screening for Fabry disease: current status of knowledge. Int J Neonatal Screen. 2023;9(2):31.","journal-title":"Int J Neonatal Screen"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03940-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03940-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03940-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:13:41Z","timestamp":1757348021000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03940-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,10]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3940"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03940-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,10]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the principles of the Helsinki Declaration, obtaining informed consent from all patients and approval from the Clinical Research Ethics Committee of the Fourth Affiliated Hospital of Soochow University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consents about data publication were obtained from all patients. The manuscript has been read and approved by all authors. All authors believe that the manuscript represents honest work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"417"}}